SCHEMBL24313342

SCHEMBL24313342

O=Cc1ccc(Oc2ccc(C=O)c(Br)c2)cc1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.48
ALDH1A1 P00352 7/20 0.47
TRIM24 O15164 2/20 0.46
TRIM33 Q9UPN9 2/20 0.46
TYR P14679 1/20 0.46
ERN1 O75460 5/20 0.41
LMNA P02545 4/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2C9 P11712 1/20 0.39
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP2A6 P11509 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29558007 1.00 PRKDC (0.48) PRKDCALDH1A1TRIM24TRIM33TYR
SCHEMBL1134249 0.91 LMNA (0.50) PRKDCALDH1A1ERN1LMNACYP1A2
SCHEMBL24313432 0.89 PRKDC (0.41) PRKDCALDH1A1TRIM24TRIM33TYR
SCHEMBL1134243 0.86 ALDH1A1 (0.53) PRKDCALDH1A1TRIM24TRIM33TYR
SCHEMBL437463 0.85 ALDH1A1 (0.66) PRKDCALDH1A1TRIM24TRIM33TYR
SCHEMBL24313440 0.85 PRKDC (0.41) PRKDCALDH1A1TRIM24TRIM33TYR
SCHEMBL13111360 0.83 ALDH1A1 (0.50) ALDH1A1ERN1LMNACYP2C19CYP2C9
SCHEMBL1134294 0.83 LMNA (0.57) ALDH1A1ERN1LMNASMN1; SMN2
Ethane SCHEMBL28205235 0.83 ALDH1A1 (0.63) PRKDCALDH1A1TRIM24TRIM33TYR
SCHEMBL21856143 0.81 PRKDC (0.41) PRKDCALDH1A1TRIM24TRIM33TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220096441-A1 TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220096441-A1 TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS PKD2, PKD1, MUC1 PRKDC 77/4885ALDH1A1 3071/4885TRIM24 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.